First-Line Use of Second-Generation Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia
Oncology nurses play a pivotal role in monitoring patients with Ph+ CML, from those who are newly diagnosed to others who may have been receiving TKI treatment for years. Indications, dosing, and characteristics of second generation oral TKIs, including potential drug-drug interactions and adverse events, and how best to manage them, are explored in this article.
The first of two case studies of representative patients presented to provide an understanding of treatment considerations for Ph+ CML.
The second of two case studies of representative patients presented to provide an understanding of treatment considerations for Ph+ CML.
Supportive care and symptom management traditionally have been the focus of treatment for patients with myelodysplastic syndrome (MDS). Recent advances in therapeutic modalities, however, have increased the lifespan of patients with MDS, who are now receiving red blood cell transfusions for their chronic anemia, resulting in iron overload. This case looks at a 71-year-old man who received a bone marrow biopsy, which found dysplasia and ringed sideroblasts but no myeloid blasts.
Frequent blood transfusions are necessary in sickle cell disease to manage chronic— often severe—anemia. Chronic transfusions can lead to iron overload, manifestations that may appear indirectly as endocrine function disorders, such as hypothyroidism. Testing, however, can reveal the underlying cause. This study looks at a 32-year-old woman who was diagnosed with chronic anemia due to hemolysis of the sickled red cells.
Case 1: In Betathalassemia, Low Liver Iron Does Not Necessarily Indicate That Cardiac Iron is Not Present
Liver iron has long been thought to be a reliable indicator of total body iron burden, including the likelihood of cardiac iron. In patients with beta-thalassemia, however, that is not always the case. This study looks at a 12-year-old girl of South Asian descent who switched to deferasirox after her tranfser at the thalassemia treatment center.
This article addresses the most common diseases in which iron overload can be problematic: betathalassemia, SCD, and MDS. Discussed are the cellular and molecular mechanisms of iron metabolism; the pathophysiology of beta-thalassemia, SCD, and MDS; the development of chronic transfusional iron overload; signs and symptoms of the condition; monitoring patients; the role of nurses in iron chelation therapy; medications used to treat iron overload; and improving patient management, patient education, and adherence to therapy.
- New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes
- What are immune checkpoints and how do they work?
- Among patients with myeloma undergoing chemo, high exercise compliance linked with reduced fatigue
- Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: A meta-analysis of Phase III randomized controlled trials
- New combination treatment effective against cutaneous metastatic melanoma
- Religiousness and spirituality have a significant impact on cancer patients' overall health and outcomes
- Dietary intervention primes triple-negative breast cancer cells for targeted therapy
- Lung cancer patients who stop smoking live longer
- Study uses dog sledding to demonstrate benefits of adapted physical activities for children with cancer
- Review examines strategies for hospital room surface cleanliness
- Patient-centered toolkit (PCTK) improves communication between patients, caregivers, and health care team
- Prophylactic surgery rates among men with breast cancer nearly double
- Fungal infection drug for lung transplant recipients may increase cancer, death risk
- Long-term denosumab therapy safe for patients with breast, prostate cancer
- Children receiving intermediate, high dose MTX experience poor CINV control
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|